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Acute myeloid leukemia is an aggressive disease characterized by clonal proliferation
and differentiation into immature hematopoietic cells of dysfunctional myeloid
precursors. Accumulating evidence shows that CD34+ CD38− leukemia stem cells
(LSCs) are responsible for drug resistance, metastasis, and relapse of leukemia. In
this study, we found that Nanog, a transcription factor in stem cells, is significantly
overexpressed in CD34+ populations from patients with acute myeloid leukemia and
in LSCs from leukemia cell lines. Our data demonstrate that the knockdown of Nanog
inhibited proliferation and induced cell cycle arrest and cell apoptosis. Moreover, Nanog
silencing suppressed the leukemogenesis of LSCs in mice. In addition, we found that
these functions of Nanog were regulated by the insulin-like growth factor receptor
(IGF1R) signaling pathway. Nanog overexpression rescued the colony formation ability of
LSCs treated with picropodophyllin (PPP), an IGF1R inhibitor. By contrast, knockdown
of Nanog abolished the effects of IGF2 on the colony formation ability of these LSCs.
These findings suggest that the IGF2/IGF1R/Nanog signaling pathway plays a critical
role in LSC proliferation.
Keywords: Nanog, IGF2, IGF1R, proliferation, leukemia stem cells

INTRODUCTION
Acute myeloid leukemia is a cancer of myeloid blood cells in the bone marrow (Fialkow
et al., 1987). Despite progress made in the treatment of AML, most patients suffer relapses
of the disease (Carella et al., 2013). In the past 40 years, chemotherapy regimens for AML
generally included cytarabine in combination with anthracycline (Peloquin et al., 2013).
Abbreviations: AML, acute myeloid leukemia; IGF1R, insulin-like growth factor receptor; LSCs, leukemia stem cells.
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chemoresistance, and tumorigenesis of pancreatic cancer cells
in vitro and in vivo (Lu et al., 2013). In our previous study, we
found that Nanog was overexpressed in LSCs from leukemia cell
lines (Xu et al., 2016). However, it is not known whether Nanog
is active in LSCs and whether its function in these cells is similar
to that in solid tumor cells.
Insulin-like growth factor 1 receptor (IGF-1R), a receptor
tyrosine kinase, is activated by binding of its ligands IGF1
and IGF2 (Yuen and Macaulay, 2008). Evidence suggests that
IGF1R and its ligands are involved in the development and
progression of cancer (Baserga et al., 1997). IGF1R activation
or overexpression mediates several aspects of the malignant
phenotype (Hakam et al., 1999; Osuka et al., 2013). More
importantly, high levels of IGF1R expression are required for
leukemia-initiating cell activity in T-cell acute lymphoblastic
leukemia, and inhibition of IGF1R blocks the growth and viability
of T-cell acute lymphoblastic leukemia cells (Medyouf et al.,
2011). Recruitment of these molecules activates signaling via the
phosphatidylinositol-3-kinase (PI3K)-AKT (Baserga et al., 2003;
Manning and Cantley, 2007). In many studies phosphorylation
of IGF1R was inhibited, which reduced Akt activation, enhanced
cancer cell apoptosis, and suppressed tumor cell growth
(Chakravarti et al., 2002; Carboni et al., 2009; Hou et al., 2011).
Therefore, it is important to understand the correlation
between Nanog and its regulators. In our previous study, we
studied the correlation between Nanog and microRNAs (miR150) (Xu et al., 2016). Importantly, in other previous studies,
we found that IGF2 was overexpressed in CD34+ CD38− LSCs
(Zhang et al., 2015). Moreover, Chen et al. (2014) demonstrated
that IGF1R signaling activation in cancer cells in the presence
of cancer-associated fibroblasts expressing IGF2 can induce
Nanog expression and promote stemness, and that IGF2 secreted
by cancer cells instigates fibroblasts and bone marrow-derived
vascular progenitor cells to promote cancer progression (Xu W.
et al., 2017).
Although IGF2 and Nanog have been known to play an
important part in regulating proliferation of cancer cells,
it remains unclear as to how they cooperate in regulating
proliferation of LSCs in AML. Here, we report that Nanog
is significantly overexpressed in CD34+ cell populations from
patients with AML and in LSCs from leukemia cell lines. More
importantly, our data suggest that IGF2/IGF1R/Nanog signaling
axis plays a key role in the proliferation of LSCs.

Although these treatments can often eliminate part of the
leukemia cells and extend the life span of the patients, the 5-year
survival rate of young patients is still below 40% (Roboz and
Guzman, 2009).
Leukemia stem cells were first discovered by Lapidot et al.
(1994). According to previous studies, LSCs are considered to be
responsible for drug resistance, metastasis, and tumor initiation
and relapse (Sands et al., 2013) and have been described to have
many properties that distinguish them from the general blast
population (Felipe Rico et al., 2013). Therefore, it is important
to target these malignant cells and investigate their intricate
mechanisms to improve outcomes in patients. In recent years,
the homeodomain-containing transcription factor Nanog has
received increasing attention because of its pivotal roles in tissue
development, stem cell maintenance, and tumor progression
(Jeter et al., 2009; Zbinden et al., 2010; Noh et al., 2012).
Nanog was discovered in 2003 in a screening for factors that
maintain self-renewal of mouse embryonic stem cells (ESCs)
in the absence of leukemia inhibitory factor (LIF) signaling
pathways (Chambers et al., 2003; Mitsui et al., 2003). Together
with Sox2 and Oct4, Nanog plays an important role in regulating
self-renewal and maintaining the pluripotency of ESCs (Loh et al.,
2006; Wang et al., 2006). Nanog is expressed in leukemia cells
(Eberle et al., 2010), as well as in human solid tumors such
as glioma, hepatocellular carcinoma, prostate cancer, pancreatic
cancer, and leukemia (Eberle et al., 2010; Zbinden et al., 2010;
Jeter et al., 2011; Shan et al., 2012; Lu et al., 2013). Moreover,
accumulating evidence demonstrates that Nanog is essential
for cancer cell proliferation, invasion, clonogenic growth, and
tumorigenicity (Jeter et al., 2009, 2011; Zbinden et al., 2010;
Ji and Jiang, 2013). A positive association between Nanog and
tumor cell growth has also been reported (Jeter et al., 2015).
Although it is not known whether this phenomenon is important
to cell growth, increased proliferation is essential to tumor cells
(Hanahan and Weinberg, 2011).
Ectopic expression of Nanog in human embryonic kidney
HEK293 cells induces cell proliferation, anchor-independent
growth in soft agar and, most importantly, tumor formation in
athymic nude mice (Lin et al., 2011). By contrast, depletion of
Nanog inhibits proliferation, reduces invasion, and is associated
with increased apoptosis and S-phase arrest in human gastric
cancer cells (Ji and Jiang, 2013). Other reports showed that Nanog
regulates growth and proliferation of cancer stem cells (CSCs) in
human hepatocellular carcinoma and glioma stem cells (Zbinden
et al., 2010; Shan et al., 2012). In addition, Nanog promotes drug
resistance, cell migration, and epithelial–mesenchymal transition
(Chiou et al., 2010; Jeter et al., 2011). Depletion of both Nanog
and Oct4 inhibits expression of the key epithelial–mesenchymal
transition factor Slug and blocks tumorigenic and metastatic
capacity in lung adenocarcinoma cells, as well as improves the
mean survival of immunocompromised mice (Chiou et al., 2010).
Moreover, Nanog knockdown reduces self-renewal, which is
associated with decreased expression of stemness genes, that
could be restored by overexpression of Nanog in Nanog-negative
human hepatocellular carcinoma cells (Shan et al., 2012). Other
studies have shown that double knockdown of Nanog and
Oct4 significantly reduces proliferation, migration, invasion,
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MATERIALS AND METHODS
Primary Cell Isolation
Leukemia stem cells from human leukemia cell lines KG-1a
and MOLM13 were isolated and identified according to the cell
markers CD34+ CD38− , as we previously described (Zhang et al.,
2015, 2016; Xu et al., 2016), and cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 1% penicillin
and streptomycin at 37◦ C under a humidified atmosphere of
5% CO2 . LSCs from KG-1a and MOLM13 were isolated using
a magnetic-activated cell-sorting (MACS) kit (Cat No. 130-056701; Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured
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in serum-free IMDM (STEMCELL Technologies, Vancouver, BC,
Canada) containing 20 ng/mL basic fibroblast growth factor
(bFGF; PeproTech, Rocky Hill, NJ, United States), 20 ng/mL
epidermal growth factor (EGF; PeproTech), and B27 media (1:50;
Life Technologies, Carlsbad, CA, United States).
Human peripheral blood samples were collected from The
First Affiliated Hospital of Jinan University. The blood of
patients with AML was sampled, and all the participants
provided informed consent. The study protocol was approved
by the ethics committee of The First Affiliated Hospital of
Jinan University. Mononuclear cells were obtained using density
gradient centrifugation, and CD34+ leukemia cells were enriched
by magnetic microbeads (Miltenyi Biotec). The CD34+ leukemia
cells were cultured in hematopoietic stem cell medium (Stem Cell
Technologies, Vancouver, BC, Canada) supplemented with B27
(Gibco, Grand Island, NY, United States), 20 ng/mL EGF, and
20 ng/mL bFGF.

Sphere Formation and Soft Agar Assays
For sphere formation, according to our previous studies (Xu
et al., 2016; Zhang et al., 2016), for sphere formation assay,
500 LSCs were cultured in an ultralow attachment 6-well plate
with IMDM medium (STEMCELL Technologies, Vancouver,
BC, Canada) with recombinant human EGF (20 ng/ml; Pepro
Tech), recombinant human bFGF (20 ng/ml, Pepro Tech),
B27 supplement (1:50, Invitrogen, Carlsbad, CA, United States)
without different concentration of IGF2 and PPP. Culture media
was replenished every 3 days about 2 weeks later, the number
of LSCs formation was counted and the colonies efficiency
(more than 50 cells) was calculated. For soft agar assay, a
6-well plate was coated with bottom agar layer containing
IMDM supplemented with recombinant human EGF (20 ng/mL),
recombinant human bFGF (20 ng/mL), B27 supplement (1:50),
and different concentration of IGF2 or without IGF2. Top
agar contained a single cell suspension of 500 LSCs in IMDM
supplemented with recombinant human EGF (20 ng/mL),
recombinant human bFGF (20 ng/mL), B27 supplement (1:50),
and different concentrations of IGF2 or without IGF2. After
25 days, colonies of more than 50 cells were visualized as positive
and stained with 0.5% crystal violet for 30 min at 37◦ C (Song
et al., 2014).

Reagents and Lentiviral Infections
The IGF1R inhibitor picropodophyllin (PPP) and 5-bromo20 -deoxyuridine (BrdU) were purchased from Sigma-Aldrich
(St. Louis, MO, United States). Nanog-targeting shRNA
lentiviral constructs were purchased from GeneChem
(Shanghai, China). The sequences of these shRNAs are 50 GGGTTAAGCTGTAACATACTT-30 for Nanog1 shRNA,
targeting the 30 -UTR, and 50 -GCATGCAGTTCCAGCCAAATT30 for Nanog2 shRNA, targeting the coding sequence (Zaehres
et al., 2005; Zbinden et al., 2010; Shan et al., 2012). Nanog
vector (pcDNA3.1-Nanog) was purchased from GenePharma
(Shanghai, China) (Xu et al., 2016). LSCs were transduced with
lentiviral constructs in a medium containing 5 µg/mL polybrene,
according to the manufacturer’s protocol.

Quantitative Polymerase Chain Reaction
(qPCR)
Total RNA was extracted from LSCs with Trizol Reagent
(Tiangen, Beijing, China), treated with RNAse-free DNAse
(Takara Biotechnology, Dalian, China), and reversetranscribed into cDNA using PrimerScript Master mix (Takara
Biotechnology) according to the manufacturer’s instructions.
qPCR was performed on an RT-PCR system (CFX96 Real-Time
System; Bio-Rad, Shanghai, China) using appropriate primers
(Sangon Biotech, Shanghai, China). In clinical samples, Nanog
and IGF1R mRNA expression levels were calculated relative to
those in normal blood. The following PCR conditions were used
on a Light Cycler: 95◦ C for 5 s, 60◦ C for 5 s, followed by 42 cycles
at 95◦ C for 15 s, and 60◦ C for 1 min in a 20-µL reaction volume.
Gene-specific primers are shown in Supplementary Table S1.
Relative expression level was calculated using the 2−(11Ct)
method with GAPDH as the reference gene. All the experiments
were replicated thrice. Student’s t-test was used to evaluate the
differences between mRNA expression levels of the two groups.
SPSS 19.0 (SPSS Inc., Chicago, IL, United States) was employed
to calculate the difference.

Proliferation and Apoptosis Assays
Leukemia stem cell proliferation analysis was assessed by using
trypan blue (Beyotime, Haimen, China). LSCs (1 × 104 ) were
seeded into a 48-well plate containing 200 µL of serum-free
IMDM media supplemented with 20 ng/mL bFGF, 20 ng/mL
EGF, and B27 media (1:50). Subsequently, the 48-well plate
was incubated for 4 h at 37◦ C in 5% CO2 in a humidified
incubator. After 72 h, the LSCs were counted by trypan blue
staining. For detection of the cell proliferation marker Ki-67,
1 × 105 LSCs were incubated with an antibody against Ki-67
(Cell Signaling Technology) and washed three times with Trisbuffered containing 0.1% Tween-20. Subsequently, the cells were
incubated with an FITC-conjugated goat secondary antibody
for 0.5 h at 37◦ C. Nuclei were counterstained with DAPI. The
cells were photographed by fluorescence microscope (Carl Zeiss,
Thornwood, NY, United States) (Xu et al., 2016). For apoptosis
assessment, LSCs were transfected with shRNAs and cultured
for 72 h. The cells were collected, washed, and 5 µL of binding
reagent and 5 µL of annexin V-APC (KeyGen Biotech, Nanjing,
China) were added. After 30 min, cells were washed thrice with
PBS and stained with 5 µL of 7-AAD for 20 min, according to
the manufacturer’s instructions. The experiments were repeated
thrice. All data were analyzed by using the FlowJo software (San
Diego, CA, United States).
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Western Blot Analysis
Treated LSCs were lysed with RIPA (Tiangen), proteins
were subjected to SDS-PAGE, and transferred to a PVDF
membrane (Immobilon-PSQ transfer membrane, Millipore,
NY, United States). The membrane was washed in blocking
buffer [5% skimmed milk (Gibco) containing 0.1% Tween20] and incubated with antibodies overnight. The dilution of
the primary antibodies against Nanog (#3580, Cell Signaling
Technology; #ab190250, Abcam; #AF1997, R&D Systems) was
1:1000. Antibodies against IGF1R, p-IG1R, Akt, and p-Akt were
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purchased from Cell Signaling Technology, and the dilutions
were 1:1000 according to the manufacturer’s instructions. The
following day, the membrane was washed by TBST buffer
(0.1% Tween-20 in Tris-base) thrice. The membrane was
incubated with horseradish peroxidase-conjugated secondary
antibodies (1:5000). The bound proteins were detected using
chemiluminescence detection kit ECL (Millipore). GAPDH was
used as an internal control. The images were acquired on a
Canon scanner (Canon, Tokyo, Japan) and processed by Adobe
Photoshop CS5 (San Jose, CA, United States). The relative density
of bands was determined by using the Image J software (NIH,
Bethesda, MD, United States).

RESULTS
Nanog Is Highly Expressed in Leukemia
Stem Cell Populations and Promotes
Leukemia Stem Cell Proliferation
The expression level of Nanog in LSCs was analyzed in
CD34+ cells isolated from blood samples of patients with
AML (Supplementary Table S2) using MACS according to our
previous study (Zhang et al., 2015) and in CD34+ CD38−
LSCs isolated from AML cell lines KG-1a and MOLM13.
There was a significant increased expression of Nanog in
patients CD34+ cells, as compared with in normal control
(Figure 1A). qPCR analysis demonstrated that Nanog mRNA
levels were significantly higher in CD34+ leukemia cells than
in CD34− counterparts (Figure 1B), and overexpressed in
LSCs (CD34+ CD38− ) (Figures 1C,D). In addition, the mRNA
levels of Sox2 and Bmi1 were higher in KG-1a LSCs than
in non-LSCs (CD34+ CD38+ , CD34− CD38+ , CD34− CD38− )
(Supplementary Figure S1).
To explore the biological role of Nanog in LSCs, we
performed shRNA experiments to target Nanog mRNA. The
efficiencies of shRNAs against Nanog are shown in Figure 1E.
shNanog1 and shNanog2 markedly resulted in a decrease
in Nanog of approximately 60–70% at the RNA level and
protein level. We found that Nanog shRNAs significantly
reduced cell proliferation of KG-1a LSCs and MOLM13
LSCs compared with a control shGFPctrl (Figures 1F,G).
We further investigated the spheroid formation capacity of
LSCs cultured in IMDM supplemented with 20 ng/mL EFG,
20 ng/mL bFGF, 100 ng/mL IGF2, and B27 in soft agar
plate experiments. The results showed that both shNanog1 and
shNanog2 significantly decreased colony formation efficiencies
of KG-1a LSCs and MOLM13 LSCs (Supplementary Figure
S2). Consistently, BrdU incorporation analysis demonstrated
that silencing of Nanog resulted in a 30–40% reduction
in cell proliferation (Figure 1H). Altogether, these results
demonstrate that Nanog plays an important role in regulating
LSC proliferation.

BrdU Incorporation Assay
Cells were fixed in 4% paraformaldehyde at room temperature
for 20 min and washed thrice. Next, the cells were permeabilized
with 0.1% Triton X-100 for 30 min and washed thrice. The cells
were incubated with mouse anti-BrdU primary antibody at room
temperature for 1.5 h after blocking with 10% anti-goat serum
in PBS. Then, cells were incubated with secondary antibody
conjugated with Alexa Flour 488 and visualized using confocal
microscopy (Carl Zeiss, Thornwood, NY, United States).

Animal Experiments
NOD/SCID and BALB/c mice were housed and bred under
specific pathogen-free conditions. All animal procedures were
approved by and conducted according to the Jinan University
Laboratory Animal Ethics Committee.
In the xenograft model, mice were divided into two groups.
Female NOD/SCID mice (5-week-old, n = 6) were intravenously
injected via the tail vein with 2 × 105 LSCs in which Nanog
was depleted, using Nanog1 shRNA. In the negative control
group, mice (n = 6) were intravenously injected via the tail
vein with 2 × 105 LSCs transduced with a control shRNA
(shGFPctrl) lentiviral vector. Mice were euthanized after 60 days,
and peripheral blood, bone marrow, and spleens were collected.
Human leukemia cells from mouse tissues were evaluated by flow
cytometry. Human leukemia cells were identified as CD45+ cells
(hCD45+ ) (Ferretti et al., 2012).
In the subcutaneous model, female BALB/c mice (5-week-old,
n = 6) were inoculated subcutaneously in the flank with 2 × 105
LSCs in which Nanog was silenced using Nanog1 shRNA. In the
negative control group, mice (n = 6) were injected with 2 × 105
LSCs transduced with shGFPctrl lentiviral vector. After 4 weeks,
the mice were euthanized, and the weight of tumors harvested
from the mice was measured.

Nanog Knockdown Induces Cell Cycle
Arrest and Apoptosis of Leukemia Stem
Cells
To further investigate the function of Nanog on LSCs
proliferation, we conducted flow cytometric analysis to compare
the cell cycle profiles of LSCs treated with Nanog shRNA. 7AAD/annexin V-APC analysis demonstrated that knockdown
of Nanog significantly increased the number of apoptotic cells
at both the early and late stage of apoptosis (Figure 2A). The
percentage of cells in subG1 phase was significantly increased
upon treatment of Nanog knockdown in both KG-1a LSCs
and MOLM13 LSCs (Figure 2B). The subG1 percentages in
shNanog1 and shNanog2-treated versus shGFPctrl-treated KG1a LSCs were 44.87, 65.26, 8.52%, respectively (Figure 2B).
Also, The subG1 percentages in shNanog1 and shNanog2treated versus shGFPctrl-treated MOLM13 LSCs were 21.28,

Statistical Analysis
Data are presented as the mean ± standard deviation (SD).
Student’s t-test was used to compare differences in cell
proliferation, apoptosis, cell cycle arrest, sphere size, and mRNA
expression levels between the groups. Correlations between the
levels of Nanog and IGF1R were assessed using Spearman’s rank
correlation analysis. All analyses were performed using SPSS
version 19 (SPSS Inc., Chicago, IL, United States). P-value < 0.05
was considered statistically significant, ∗ P < 0.05 and ∗∗ P < 0.01.
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FIGURE 1 | Nanog is highly expressed in leukemia stem cell (LSC) populations, and promotes LSC proliferation. (A) qPCR analysis of Nanog mRNA level in a panel
of 16 samples of leukemia cells derived from patients with AML. (B) Nanog mRNA level in CD34+ cells of patients with AML compared with the counterpart CD34−
cells. (C,D) qPCR analysis of Nanog mRNA level in LSCs from KG-1a and MOLM13 cell lines. (E) qPCR (a,b) and western blot (c,d) analysis of the knockdown
efficiency of shNanog1 and shNanog2. (F,G) Proliferation curve analysis of LSCs after silencing of Nanog. Cells (1 × 104 ) were stably transduced with lentiviral
constructs carrying shGFPctrl, shNanog1, or shNanog2. After 72 h, proliferation of LSCs was analyzed by trypan blue staining. The experiments were repeated three
times independently (∗ P < 0.05). (H) BrdU analysis of LSC proliferation after knockdown of Nanog. Immunofluorescence expression analysis of Nanog using a rabbit
monoclonal antibody after silencing of Nanog. Grayscale analysis was done by using ImagePro Plus (∗ P < 0.05). Scale bar, 100 µm.
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FIGURE 2 | Nanog knockdown induces cell cycle arrest and apoptosis of LSCs. (A) Flow cytometry analysis of apoptosis after Nanog knockdown. LSCs were
transduced with shNanog1, shNanog2, or shGFPctrl. Following 48 h, apoptosis was evaluated by flow cytometry. The experiments were repeated independently
three times (∗ P < 0.05). Data are presented as the mean ± SD. (B) Flow cytometry analysis of subG1 percentages in LSCs of KG-1a and MOLM13 cell lines was
conducted by using the FlowJo software. The experiments were repeated independently in triplicate (∗ P < 0.05). (C–E) Cell viability after knockdown of Nanog. In
total, 5 × 103 cells transduced with lentiviral vector were seeded in IMDM containing Ara-C, L-Asp, or dexamethasone. After culture for 48 h, CCK-8 was added to
the cell culture and incubated for 4 h. Absorbance was recorded at 450 nm by using a microplate absorbance reader (n = 3).

Frontiers in Pharmacology | www.frontiersin.org

6

June 2018 | Volume 9 | Article 687

Xu et al.

IGF2/Nanog Regulates Proliferation

17.39, 7.35%, respectively (Figure 2B). To further investigate
the cell viability of LSCs after Nanog silencing, the three
drugs Ara-C, L-Asp, and dexamethasone were used for
leukemia treatment. As shown in Figure 2C, LSCs were more
sensitive to Ara-C after Nanog silencing. We also found
similar results with the other two drugs (Figures 2D,E).
Taken together, these results demonstrated that knockdown of
Nanog induces cell apoptosis of LSCs and cell cycle arrest
at the G0/G1 phase and decreases the drug resistance of
LSCs.

The IGF2 Signaling Pathway Is Essential
in the Regulation of Nanog Expression in
Leukemia Stem Cells
In our previous study, we found that IGF2 is highly expressed
in CD34+ CD38− KG-1a cells (Zhang et al., 2015). Therefore,
we investigated whether IGF2 signaling influences Nanogmediated LSC proliferation. Sphere formation assays showed
that similar to Nanog knockdown, treatment with IGF2
significantly increased the colony formation efficiencies of
LSCs (Figure 5A). The immunofluorescence results showed
that IGF2 significantly promoted the proliferation of LSCs
according to the expression level of Ki-67 (Figure 5B).
Furthermore, we found that treatment with IGF2 increased
the phosphorylation levels of IGF1R and its downstream
protein Akt in a time-dependent manner (Figures 5C,D).
More importantly, treatment with IGF2 significantly elevated
Nanog expression both in KG-1a LSCs and MOLM13 LSCs
(Figures 5C,D). In addition, Nanog knockdown abrogated the
pro-proliferative effect of IGF2 (Supplementary Figure S3). These
results suggest that IGF2/IGF1R signaling is activated upstream
of Nanog.

Nanog Depletion Suppresses Stemness
Factor Levels and Colony Formation
Chiou et al. (2008) showed positive correlations between Nanog
and Oct4 in oral cancer stem-like cells and in high-grade
oral squamous cell carcinoma. In addition, co-expression of
Oct4 and Nanog enhances malignancy in lung adenocarcinoma
by inducing CSC-like properties and epithelial–mesenchymal
transition (Chiou et al., 2010). Therefore, we questioned the
relation between Nanog and other stemness factors. We thus
performed qPCR experiments to analyze the expression level
of stemness factors. As expected, the expression levels of Sox2
and Bmi1 were decreased in both LSCs (Figures 3A,B). We
also examined p-STAT3 expression level and found that in both
LSCs, Nanog depletion reduced p-STAT3 level (Figures 3C,D).
Moreover, Nanog knockdown suppressed the growth and
proliferation of LSCs, as determined by a colony formation assay
(Figure 3E).

Inhibition of IGF1R Suppresses the
Expression Level of IGF2-Induced Nanog
Insulin-like growth factor receptor activation or overexpression
mediates several aspects of the malignant phenotype (Hakam
et al., 1999; Osuka et al., 2013). Thus, we tested IGF1R mRNA
levels in several leukemia cell lines. We found that IGF1R
mRNA level was significantly higher in leukemia cells than
in normal blood (Figure 6A). Next, we evaluated IGF1R and
Nanog expression levels in blood samples from patients with
AML. As shown in Figure 5B, IGF1R mRNA expression showed
a highly significant (P < 0.0001) positive correlation with
Nanog mRNA expression in CD34+ leukemia cells (Figure 6B).
Furthermore, we found that IGF1R inhibitor PPP reversed
IGF2-induced Nanog expression (Figures 6C,D), as well as
IGF2-induced IGF1R and Akt phosphorylation (Figures 6C,D).
In addition, we examined whether IGF1R was important in
LSC proliferation. As expected, the results of sphere formation
experiments demonstrate that PPP significantly decreased colony
formation efficiencies (Figure 6E). Moreover, PPP inhibited LSC
proliferation, which was rescued partly by Nanog overexpression
(Supplementary Figure S4). Taken together, these results suggest
that extracellular IGF2 signaling is responsible for Nanog
expression in LSCs.

Nanog Knockdown Impairs
Leukemogenesis of Leukemia Stem
Cells in Vivo
To investigate the biological role and function of Nanog in vivo,
we first established xenograft tumor models with KG-1a LSCs and
MOLM13 LSCs and evaluated the effect of Nanog knockdown
on tumor growth. Knockdown of Nanog remarkably suppressed
the growth of KG-1a LSC xenograft tumors, as well as MOLM13
LSC xenograft tumors, in BALB/c nude mice (Figure 4A).
The mean weight of excised tumors in Nanog-knockdown
xenograft was threefold smaller than that in control tumors
(Figure 4A). Furthermore, western blot analysis confirmed
Nanog downregulation in Nanog-knockdown xenograft tumors
(Figure 4B).
To further confirm the tumorigenic function of Nanog in
LSCs, immunodeficient NOD/SCID mice were injected with
KG-1a LSCs transduced with shGFPctrl or shNanog1 via
the tail vein. Representative images of hCD45+ staining in
peripheral blood, bone marrow, and spleen obtained from
NOD/SCID mice are shown in Figure 4C. As expected, the
proportion of hCD45+ cells was 17-fold lower in peripheral
blood from mice injected with KG-1a LSCs treated with
shNanog1 than in that treated with shGFPctrl (Figure 4C).
Similar results were obtained in bone marrow and spleen
(Figure 4C). These results suggest that Nanog plays an
important role in regulating the leukemogenesis function of
LSCs.
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DISCUSSION
Acute myeloid leukemia is a stem cell-related disease consisting
of hematopoietic neoplasms, with a decreased capacity to
differentiate into normal and mature cells (Peloquin et al., 2013).
Laboratory research data suggest that AML originates from a
subset of a rare population of cells that are capable of self-renewal
and differentiation into malignant blasts (Roboz and Guzman,
2009).
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FIGURE 3 | Silencing of Nanog suppresses stemness factor levels and proliferation of LSCs. (A,B) qPCR data demonstrate that the levels of Sox2 and Bmi1 was
decreased. LSCs were transduced with lentiviral vector. After 72 h, LSCs were harvested. The experiments were repeated independently three times (∗ P < 0.05).
Data are presented as the mean ± SD. (C,D) Western blot analysis shows that p-STAT3 level was reduced. LSCs were transduced with lentiviral vectors. After 72 h,
LSCs were harvested and analyzed. (E) Soft agar plates experiments demonstrate that Nanog knockdown inhibited the proliferation of LSCs. LSCs (500) were
seeded in IMDM with IGF2 (20 ng/mL), EGF (20 ng/mL), bFGF (20 ng/mL), B27 supplement (1:50). After 2 weeks later, the colonies of LSCs were large enough to be
visualized, and were stained with 0.5% crystal violet for 30 min at 37◦ C.
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FIGURE 4 | Knockdown of Nanog impairs LSC growth in vivo. (A) BALB/c nude mice were injected subcutaneously with KG-1a LSCs or MOLM13 LSCs
transduced with shGFPctrl or shNanog1 and shNanog2. In total, 2 × 105 treated cells were injected subcutaneously into BALB/c nude mice. Tumors were
harvested at 30 days after injection. Data are presented as the mean ± SD (∗ P < 0.05). (B) Western blot analysis of Nanog protein level excised from tumors.
(C) Representative experiment data of hCD45 expression in PB, BM, and spleen harvested from NOD/SCID mice injected with shGFPctrl (Top) or shNanog1
(Bottom) KG-1a LSCs. NOD/SCID mice were injected via the tail vein with 2 × 105 KG-1a LSCs. Mice were euthanized 60 days after injection. PB, BM, and spleen
were collected and subjected to analysis. PB, peripheral blood; BM, bone marrow.
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FIGURE 5 | Insulin-like growth factor (IGF) signaling regulates Nanog expression and LSC growth. (A) IGF2 significantly increased the colony formation efficiencies of
KG-1a LSCs and MOLM13 LSCs. LSCs were cultured in IMDM containing bFGF (20 ng/mL), EGF (20 ng/mL), and B27. All data represent three independent
experiments for each condition (∗ P < 0.05). Scale bar, 100 µm. (B) Treatment with IGF2 promoted LSC proliferation. LSCs were cultured in IMDM containing bFGF
(20 ng/mL), EGF (20 ng/mL), and B27 with or without IGF2 (100 ng/mL) for 72 h. The cells were then harvested and incubated with an antibody against Ki-67. Scale
bar, 60 µm. (C,D) Western blot analysis showed that IGF2 increased p-IGF1R, p-Akt, and Nanog expression levels in a time-dependent manner. GAPDH was used
as a loading control. The experiments were independently repeated three times.
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FIGURE 6 | Inhibition of IGF1R suppresses LSC proliferation. (A) qPCR analysis of IGF1R expression in healthy PB cells and leukemia cell lines. Data are presented
as the mean ± SD (∗∗ P < 0.01). (B) Correlation between Nanog and IGF1R mRNA expression levels as determined by qPCR and Spearman’s analysis (∗ P < 0.05).
Normal blood was used as internal control. (C,D) Western blot analysis of p-IGF1R, p-Akt, and Nanog expression after IGF1R inhibition by PPP (0.1 µM) in both LSC
lines. (E) Colony formation detection of LSCs upon addition of IGF2 and the IGF1R inhibitor PPP. Scale bar, 100 µm. PB, peripheral blood; PPP, picropodophyllin.

in vitro and progressively abolishes leukemogenesis in vivo. Our
research strongly suggests that Nanog is important for LSC
proliferation. Moreover, we found evidence that Nanog regulates
the proliferation of LSCs, which is mediated directly by the
IGF2 signaling axis. Nanog is overexpressed in cancer cells

Here, we describe a critical role for Nanog in the regulation
of LSC proliferation. Our results demonstrate that Nanog is
overexpressed in patient-derived CD34+ leukemia cells and
in CD34+ CD38− LSCs from leukemia cell lines. We show
that depletion of Nanog decreases the proliferation of LSCs
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studies other stemness facors Nanog, Oct4, and Sox2 play a key
role in regualting ESCs and CSCs (Torres and Watt, 2008; Jeter
et al., 2009; Zbinden et al., 2010).
In our study, IGF1R was essential for the proliferation of
LSCs. Inhibition of IGF1R by PPP blocked Nanog expression
and attenuated the colony formation capacity of LSCs. IGF1R is
critical for tumorigenesis (Keku et al., 2012), particularly for the
development and progression of tumorigenesis (Liu et al., 2014).
The IGF1R signaling pathway is implicated in the pathogenesis
and progression of cancer (Jenkins et al., 2012). High level of
IGF1R expression is required for leukemia-initiating cell activity
in T-ALL, and inhibition of IGF1R blocks the growth and
viability of T-ALL cells (Medyouf et al., 2011). Additionally,
IGF1R plays an important role in tumor cell metastasis and
survival of malignant tumor cells (Sachdev et al., 2010), and
is essential for the regulation of adaptive radioprotection in
glioma stem cells (Osuka et al., 2013). Therefore, promising
therapeutic agents targeting the IGF1R pathway include IGF1R
monoclonal antibodies, IGF1R tyrosine kinase inhibitors, and
IGF ligand-specific antibodies, which show good efficacy (Liu
et al., 2014).

(Jeter et al., 2009, 2011; Pan et al., 2010; Zbinden et al., 2010; Du
et al., 2012, 2013; Shan et al., 2012; Zhang et al., 2013; Wang et al.,
2017) and in this study, we found that Nanog is overexpressed
in CD34+ cells of patients with AML and in CD34+ CD38− cells
of leukemia cell lines. In clinical samples, the expression level of
Nanog was higher in CD34+ cells than in CD34− cells. However,
the level of Nanog in normal blood cells remains unclear. Hence,
Nanog as a potential therapeutic target in AML needs to be
studied further.
Several studies have shown that Nanog regulates selfrenewal of cancer cells and CSCs. Nanog regulates self-renewal
of prostate, breast, and colon cancer cells, and knockdown
of Nanog inhibits tumor development in vivo (Jeter et al.,
2009). Additionally, Nanog regulates self-renewal of human
hepatocellular carcinoma and is essential in regulating the growth
of glioma stem cells (Zbinden et al., 2010; Shan et al., 2012).
Consistent with these reports, our results show that knockdown
of Nanog inhibits growth, and induces apoptosis and G0/G1
cell cycle arrest in LSCs. We demonstrate that silencing of
Nanog reduced the growth properties of LSCs, including colony
size.
However, the molecular mechanisms underlying Nanogmediated proliferation of LSCs remain largely unknown.
Understanding these mechanisms is essential to develop new
strategies to target these cells. In this investigation, silencing
of Nanog inhibited the proliferation of LSCs. This may be a
transcriptional reprogramming effect mediated by Nanog. This
hypothesis is consistent with the finding that Nanog is required
for maintenance of self-renewal and pluripotency in ESCs
(Chambers et al., 2003; Mitsui et al., 2003; Boyer et al., 2005; Loh
et al., 2006). Nanog overexpression accelerates reprogramming in
ESCs (Hanna et al., 2009), and the protein is critical for hindering
differentiation of pluripotent cells. In addition, we found that
Nanog expression level was positively correlated with the protein
expression of IGF1R.
Insulin-like growth factor receptor is a receptor tyrosine
kinase that is activated by binding to its ligands IGF1 and IGF2
(Yuen and Macaulay, 2008). Evidence suggests that IGF1R and
its ligands are involved in the development and progression
of cancer (Baserga et al., 1997). According to recent reports,
IGF2 abnormalities have been demonstrated in many adult
malignancies, in which its overexpression is positively correlated
with poor prognosis (Singer et al., 2004; Lu et al., 2006).
IGF2 secreted by cancer cells promotes cancer progression (Xu
W. et al., 2017), and cancer-associated fibroblasts and IGF2
regulate the plasticity of lung cancer stemness via paracrine
signaling (Chen et al., 2014). We previously found that IGF2
is overexpressed in LSCs (Zhang et al., 2015). However, the
relationship between IGF2 and Nanog in LSCs is still unclear.
Xu L. et al. (2017) demonstrated that IGF1/IGF1R/STAT3
signaling promotes gastric cancer growth and metastasis, but the
mechanism was not elucidated. The exact molecular mechanism
underlying IGF2 signaling and Nanog remains unclear. Here we
also investigated whether stemness factor level including Bmi1,
Sox2, and STAT3 were decreased after Nanog was knockdown.
STAT3, an important transcription factor, is seen a stemness
facor. STAT3 is important to both ESCs and CSCs. In many other
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CONCLUSION
Our results demonstrate that Nanog plays a key role in regulating
the proliferation of LSCs. Silencing of Nanog decreased LSC
proliferation, inducing apoptosis and cell cycle arrest and
attenuating leukemogenesis of LSCs. Furthermore, we found
that the Nanog mRNA expression-level is higher in LSCs
from leukemia cell lines and CD34+ cells from AML clinical
samples. IGF2/Nanog signaling axis regulates LSC proliferation
and leukemogenesis of LSCs through Nanog. Altogether, our
results show that the IGF2/IGF1R signaling axis is required
for Nanog-regulated maintenance of LSC proliferation and
indicate that Nanog is a downstream mediator of the IGF1R
signaling pathway. These results provide new insights into the
underlying mechanism of the IGF2/IGF1R/Nanog pathway in the
proliferation of LSCs.
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